Clinical trials: Diabetes, Type 1
Diabetes Mellitus
Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)
This clinical trial will explore the safety and effect of autologous ex vivo expanded polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent onset T1DM.
- Trial name
- NCT02691247
- Testing
- CLBS03 Low Dose, CLBS03 High Dose
- Where
- 15 sites in United States
- Volunteers
- 113 people
- Sponsor
- Lisata Therapeutics, Inc.
Type 1 Diabetes Mellitus
Pediatric Diabetics Type 1 Using InsuPatch
This study is a prospective, single-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01368978
- Testing
- InsuPatch
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Insuline Medical Ltd.
Type 1 Diabetes Mellitus
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of subcutaneously administered teplizumab in adults with relatively recent onset T1DM, greater than 12 weeks and…
- Trial name
- SUBCUE (NCT01189422)
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus
A randomized single-blind study with the use of different lancing devices equipped with personal lancets to determine and to compare the amount of capillary blood volume and perceived pain after a single lancing of the fingertip.
- Trial name
- NCT04253431
- Testing
- Droplet lancing device (HTL-Strefa S.A.), Microlet 2 lancing device (Bayer), OneTouch Delicia lancing device (LifeScan)
- Volunteers
- 60 people
- Sponsor
- HTL-Strefa S.A.
Diabetes Mellitus, Type 1
Insulin Glulisine, Diabetes Mellitus Type 1
To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy
- Trial name
- NCT00397553
- Testing
- Insulin glulisine
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT
The intended purpose of this study was to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00751842
- Testing
- rhGAD65
- Where
- 43 sites in United States
- Volunteers
- 331 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Type 1 Diabetes
PS230005 Control-IQ 1.5 Post-Approval Study
This 522 post-market surveillance study is a single-arm, decentralized prospective observational cohort study designed to collect safety data on Control-IQ technology v1.5 in children with type 1 diabetes ages 2 to <6 years old.
- Trial name
- NCT06717451
- Testing
- Control-IQ Technology v1.5
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
In Clinic Evaluation of the PLGM Feature
This study is a multi-center, single arm and in-clinic study to evaluate the safety of the PLGM System and its algorithm with the Enlite 3 Sensor.
- Trial name
- PLGM (NCT02130284)
- Testing
- Predictive Low Glucose Management Feature in Insulin pump
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the pharmacodynamic properties of two different doses of a new insulin glargine formulation with 0.4 U/kg Lantus® Secondary Objective: To compare the pharmacokinetic properties of two different doses…
- Trial name
- NCT01493115
- Testing
- Insulin glargine HOE901, Insulin glargine - New formulation HOE901
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare cognitive function and associated brain activation patterns during an acute hypoglycaemic episode and during euglycaemia (normal blood glucose concentration).
- Trial name
- NCT01789593
- Testing
- glucose clamp
- Where
- Denmark
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetic Foot Disease, Diabetic Foot Infection
Continuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot.
The goal of this clinical trial is to evaluate the performance of a self-monitoring system (Solsius SelfCare) to detect pre-ulcerative clinical abnormalities in adults living with type 1 or 2 diabetes at high podiatric risk…
- Conditions
- Diabetic Foot Disease, Diabetic Foot Infection, Diabetic Foot Infections, Diabete Type 1
- Trial name
- DIAFOOTEM (NCT07910721)
- Testing
- Solsius SelfCare
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Solsius
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of…
- Trial name
- NCT01773798
- Testing
- insulin degludec/insulin aspart 15, insulin degludec/insulin aspart, insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 2
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
Twelve smoking and twelve non-smoking subjects with Type 2 Diabetes Mellitus will be enrolled in this study to determine the effect of Technosphere® Insulin Inhalation Powder on insulin in the body during a clamp procedure.
- Trial name
- NCT00934414
- Testing
- Technosphere Insulin Inhalation Powder
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01992588
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.